Newron Pharmaceuticals SpA is a leading pharmaceutical company that represents a strong set of values and a dedicated corporate philosophy. With a commitment to innovation and the improvement of patients' lives, Newron focuses on developing novel therapeutic solutions. Their core values include integrity, accountability, and a patient-centric approach. By combining cutting-edge research, state-of-the-art technologies, and a highly skilled team, Newron strives to bring effective treatments to the market. The company's dedication to ethical practices, scientific excellence, and collaboration with key stakeholders further reinforces its mission of making a positive impact in the field of pharmaceuticals.

Newron Pharmaceuticals SpA is primarily present in Europe, with a focus on countries such as Italy, Germany, France, and Switzerland. Additionally, the company has a presence in the United States. As a leading pharmaceutical company, Newron Pharmaceuticals SpA operates globally, engaging in research, development, and commercialization of novel therapies for neurological disorders. By expanding its reach in strategic markets, including Europe and the United States, Newron Pharmaceuticals SpA aims to enhance patient access to its innovative products and address the unmet medical needs of individuals living with neurological conditions.

Newron Pharmaceuticals SpA has achieved several significant milestones. One notable accomplishment includes the successful completion of a Phase III clinical trial for their lead product, Xadago®, a treatment for Parkinson's disease. Additionally, the company has received approval for Xadago® from regulatory authorities in both the European Union and the United States. Newron Pharmaceuticals SpA has also established partnerships with global pharmaceutical companies to further develop and commercialize their innovative drug pipeline. Moreover, the company continues to focus on advancing research and development efforts to bring new treatments to patients in need.

Newron Pharmaceuticals SpA is a renowned pharmaceutical company that specializes in developing innovative therapies for patients suffering from diseases of the central nervous system. Established in 1999, Newron Pharmaceuticals SpA has shown consistent dedication towards advancing neuroscience research and providing effective treatment options. Over the years, the company has successfully built a strong foundation in the fields of neurology and psychiatry. Notably, Newron Pharmaceuticals SpA has focused on developing drugs that target unmet medical needs, particularly in rare neurological and psychiatric disorders. Through continuous research and development, Newron Pharmaceuticals SpA aims to improve the lives of patients worldwide.

The main competitors of Newron Pharmaceuticals SpA in the market include XYZ Pharmaceuticals, ABC Biotech, and DEF Therapeutics.

Newron Pharmaceuticals SpA primarily operates in the pharmaceutical industry.

Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development and commercialization of novel therapies for patients with diseases of the central nervous system. Their business model revolves around identifying high unmet medical needs and developing innovative treatments to address them. Newron leverages its scientific expertise to research, test, and seek regulatory approval for new drugs, aiming to improve the quality of life for patients suffering from neurological disorders. By combining scientific advancements and strategic partnerships, Newron Pharmaceuticals SpA aims to bring these innovative therapies to market, ultimately creating value for its shareholders and contributing to the healthcare industry.

Poměr Newron Pharmaceuticals SpA P/E je 203,98.

Koeficient Newron Pharmaceuticals SpA tržních hodnot je 6,36.

AlleAktien kvalitní skóre pro Newron Pharmaceuticals SpA je 7/10.

očekávané Newron Pharmaceuticals SpA obrat je 22,86 mil. EUR.

očekávané Newron Pharmaceuticals SpA zisk je 712 867,74 EUR.

Newron Pharmaceuticals is a biopharmaceutical company based in Milan, Italy, specializing in researching and developing novel therapies for central nervous system diseases. The company has three main divisions: research and development, manufacturing, and distribution. It has a strong pipeline of drug candidates in various stages of clinical development, with a focus on neurology and psychiatry. Newron Pharmaceuticals aims to provide innovative treatment options for patients with neurological diseases and expand its global market presence. The company's current products include Xadago, used for Parkinson's disease, and Sarizotan, being developed for Rett syndrome. Newron Pharmaceuticals aims to improve the quality of life for patients with neurological disorders through its research and development efforts. Its business model is centered around addressing the unmet needs of these patients and collaborating with other pharmaceutical companies for product development and marketing. The company is well-positioned to advance in the field of central nervous system research and meet the demands of patients with neurological diseases.

Newron Pharmaceuticals SpA vyplácí dividendu ve výši 0 EUR rozdělenou do výplat během roku.

Dividenda pro Newron Pharmaceuticals SpA momentálně nemůže být vypočítána nebo společnost žádnou dividendu nevyplácí.

ISIN společnosti Newron Pharmaceuticals SpA je IT0004147952.

WKN společnosti Newron Pharmaceuticals SpA je A0LF18.

Ticker společnosti Newron Pharmaceuticals SpA je NWRN.SW.

Během posledních 12 měsíců vyplatila společnost Newron Pharmaceuticals SpA dividendu ve výši . To odpovídá dividendovému výnosu přibližně . Pro nadcházejících 12 měsíců se očekává, že Newron Pharmaceuticals SpA vyplatí dividendu ve výši 0 EUR.

Výnos z dividend společnosti Newron Pharmaceuticals SpA aktuálně činí .

Newron Pharmaceuticals SpA vyplácí čtvrtletní dividendu. Ta je distribuována v měsících .

Newron Pharmaceuticals SpA vyplácela v posledních 0 letech každý rok dividendu.

Očekává se, že v následujících 12 měsících budou dividendy ve výši 0 EUR. To odpovídá dividendovému výnosu 0 %.

Newron Pharmaceuticals SpA je přiřazen k sektoru 'Zdraví'.

Aby ses mohl podílet na poslední dividendě Newron Pharmaceuticals SpA ve výši 0 EUR, zaznamenané 20. 9. 2024, měl jsi mít akcii ve svém portfoliu před ex-dnem 20. 9. 2024.

Poslední dividendy byly vyplaceny dne 20. 9. 2024.

V roce 2023 společností Newron Pharmaceuticals SpA bylo vyplaceno 0 EUR ve formě dividend.

Dividendy společnosti Newron Pharmaceuticals SpA jsou vypláceny v EUR.